goetzpartners securities Limited
09-Apr-2018 / 15:47 GMT/BST
Free to access research and investor meetings in a post-MiFID2 world
4SC AG (VSC-DE): Rising from the East
4SC’s Japanese partner Yakult Honsha’s (Yakult) decision to join the RESMAIN study looks a significant endorsement of the resminostat programme. While CTCL (Cutaneous T-Cell Lymphoma) is probably not itself a substantial opportunity in Japan, with Yakult’s prime focus on the more Asian-prevalent biliary cancer, it clearly demonstrates commitment from a partner that already knows the product well. Outside Japan, prospects for 4SC also look bright. Its clinical programmes appear to be progressing well. Strong news flow, including the first read out from its proof-of-concept phase II for 4SC-202 in H2/2018E, should maintain momentum for the stock over the next 6 months and beyond. Adding in the potential upside from Yakult in Japan and the expected news flow, we reiterate our OUTPERFORM recommendation and increase our target price to EUR10 (from EUR7.50).
Sound endorsement of Resminostat – While CTCL is a significantly smaller opportunity in Japan than in Europe or particularly the US (less than 25% the prevalence), Yakult’s decision to join the trial is a significant endorsement of the safety and efficacy of resminostat from a partner that has been on board since 2011.
Large Asian opportunity in biliary cancer – Yakult recently announced that they are going to initiate a phase II proof-of-concept trial with resminostat in the treatment of biliary tact cancer (“BTC”). More uncommon that in the West, BTC affects around 5400 in Japan and is even more common in parts of SE Asia and China.
News flow from pipeline – 4SC’s clinical pipeline appears to be moving forwards well. First interim read out from the 4SC-202 phase II in melanoma in combination with the check point inhibitor expected in H2/2018E with the RESMAIN CTCL trial due to report in 2019E.
Prospects for partnering – 4SC has indicated that it anticipates entering combination trials with partners in H2/2018E. Positive interim data in melanoma would certainly boost the probability of licensing for development in potential blockbuster indications.
Remains undervalued – Although the stock has performed well, given the recent endorsement from a major partner and the prospect of strong news flow, we are optimistic for more to come. Our current DCF analysis suggest a fair value of EUR8.7 rising to EUR14.6 with news flow. We reiterate our OUTPERFORM recommendation and increase our target price to EUR10 (from EUR7.50).
Dr. Chris Redhead | Analyst
goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
T +44 (0) 203 859 7725 | firstname.lastname@example.org / email@example.com
Registered in England No. 04684144.
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.
GPSL publishes and distributes “Investment” Research and “Corporate Sponsored” Research. Our Corporate Sponsored Research is free to access and is not classified as an inducement in a post-MiFID2 world. GPSL does not offer any execution or market making services.
To be added, or to change your subscriptions or be removed / unsubscribed entirely from our CRM, please e-mail: ResearchProduction@goetzpartners.com
About GPSL: goetzpartners securities Limited is a member of the goetzpartners group and a leading true pan European investment bank and research firm. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world in a yet unexperienced pace. Our sector knowledge and our global footprint bring together deep understanding of the industry, corporate intelligence and a wide network of top decision makers.
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
This e-mail (including any attachments) from goetzpartners securities Limited (“GPSL”) is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).
GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, RNS Reach and Thomson Reuters.
If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
End of Announcement – EQS News Service